Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) FCF Margin: 2019-2025

Historic FCF Margin for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -987.37%.

  • Kymera Therapeutics' FCF Margin rose 34919.00% to -987.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 96,725.63%, marking a year-over-year increase of 9689488.00%. This contributed to the annual value of -6,688.35% for FY2024, which is 651365.00% down from last year.
  • As of Q3 2025, Kymera Therapeutics' FCF Margin stood at -987.37%, which was down 87.05% from -527.88% recorded in Q2 2025.
  • Kymera Therapeutics' FCF Margin's 5-year high stood at 171.47% during Q4 2024, with a 5-year trough of -1,336.57% in Q3 2024.
  • Over the past 3 years, Kymera Therapeutics' median FCF Margin value was -456.82% (recorded in 2024), while the average stood at -483.30%.
  • Per our database at Business Quant, Kymera Therapeutics' FCF Margin slumped by 107,414bps in 2021 and then surged by 34,919bps in 2025.
  • Over the past 5 years, Kymera Therapeutics' FCF Margin (Quarterly) stood at -254.36% in 2021, then skyrocketed by 707bps to -247.28% in 2022, then skyrocketed by 23,981bps to -7.48% in 2023, then skyrocketed by 17,895bps to 171.47% in 2024, then skyrocketed by 34,919bps to -987.37% in 2025.
  • Its FCF Margin stands at -987.37% for Q3 2025, versus -527.88% for Q2 2025 and -360.26% for Q1 2025.